Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Birkett, DJ' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 40 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. McManus, P; Birkett, DJ; Dudley, J; Stevens, A
      Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia

      PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
    2. Birkett, DJ; Mitchell, AS; McManus, P
      A cost-effectiveness approach to drug subsidy and pricing in Australia

      HEALTH AFFAIRS
    3. Henry, DA; Birkett, DJ
      Changes to the Pharmaceutical Benefits Advisory Committee

      MEDICAL JOURNAL OF AUSTRALIA
    4. Miners, JO; Coulter, S; Birkett, DJ; Goldstein, JA
      Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

      PHARMACOGENETICS
    5. Ong, CE; Coulter, S; Birkett, DJ; Bhasker, CR; Miners, JO
      The xenobiotic inhibitor profile of cytochrome P4502C8

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    6. McLure, JA; Miners, JO; Birkett, DJ
      Nonspecific binding of drugs to human liver microsomes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    7. McManus, P; Henry, DA; Birkett, DJ
      Recent changes in the profile of prescription NSAID use in Australia

      MEDICAL JOURNAL OF AUSTRALIA
    8. MCMANUS P; MARLEY J; BIRKETT DJ; LINDNER J
      COMPLIANCE WITH RESTRICTIONS ON THE SUBSIDIZED USE OF PROTON PUMP INHIBITORS IN AUSTRALIA

      British journal of clinical pharmacology
    9. MINERS JO; BIRKETT DJ
      CYTOCHROME P4502C9 - AN ENZYME OF MAJOR IMPORTANCE IN HUMAN DRUG-METABOLISM

      British journal of clinical pharmacology
    10. ONG CE; MINERS JO; BIRKETT DJ; BHASKER CR
      BACULOVIRUS-MEDIATED EXPRESSION OF CYTOCHROME P4502C8 AND HUMAN NADPH-CYTOCHROME P450 REDUCTASE - OPTIMIZATION OF PROTEIN EXPRESSION

      Xenobiotica
    11. MCMANUS P; BIRKETT DJ; MANT A
      PRESCRIPTION USE BY PATIENTS WITH CONCESSION CARDS

      Medical journal of Australia
    12. WINDMILL KF; CHRISTIANSEN A; TEUSNER JT; BHASKER CR; BIRKETT DJ; ZHU XY; MCMANUS ME
      LOCALIZATION OF ARYL SULFOTRANSFERASE EXPRESSION IN HUMAN TISSUES USING HYBRIDIZATION HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY

      Chemico-biological interactions
    13. BHASKER CR; MINERS JO; COULTER S; BIRKETT DJ
      ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9

      Pharmacogenetics
    14. BHASKER CR; MINERS JO; COULTER S; BIRKETT DJ
      ALLELIC AND FUNCTIONAL VARIABILITY OF CYTOCHROME P4502C9

      Pharmacogenetics
    15. ZHANG H; COVILLE PF; WALKER RJ; MINERS JO; BIRKETT DJ; WANWIMOLRUK S
      EVIDENCE FOR INVOLVEMENT OF HUMAN CYP3A IN THE 3-HYDROXYLATION OF QUININE

      British journal of clinical pharmacology
    16. BIRKETT DJ; MINERS JO; VALENTE L; LILLYWHITE KJ; DAY RO
      1-METHYLXANTHINE DERIVED FROM CAFFEINE AS A PHARMACODYNAMIC PROBE OF OXYPURINOL EFFECT

      British journal of clinical pharmacology
    17. SULLIVANKLOSE TH; GHANAYEM BI; BELL DA; ZHANG ZY; KAMINSKY LS; SHENFIELD GM; MINERS JO; BIRKETT DJ; GOLDSTEIN JA
      THE ROLE OF THE CYP2C9-LEU(359) ALLELIC VARIANT IN THE TOLBUTAMIDE POLYMORPHISM

      Pharmacogenetics
    18. TASSANEEYAKUL W; BIRKETT DJ; PASS MC; MINERS JO
      LIMITED VALUE OF THE URINARY PHENYTOIN METABOLIC RATIO FOR THE ASSESSMENT OF CYTOCHROME P4502C9 ACTIVITY IN-VIVO

      British journal of clinical pharmacology
    19. GRAHAM S; DAY RO; WONG H; MCLACHLAN AJ; BERGENDAL L; MINERS JO; BIRKETT DJ
      PHARMACODYNAMICS OF OXYPURINOL AFTER ADMINISTRATION OF ALLOPURINOL TOHEALTHY-SUBJECTS

      British journal of clinical pharmacology
    20. MINERS JO; BIRKETT DJ
      THE USE OF CAFFEINE AS A METABOLIC PROBE FOR HUMAN DRUG-METABOLIZING-ENZYMES

      General pharmacology
    21. MCMANUS P; PRIMROSE JG; HENRY DA; BIRKETT DJ; LINDNER J; DAY RO
      PATTERN OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE IN AUSTRALIA 1990-1994 - A REPORT FROM THE DRUG UTILIZATION SUB-COMMITTEE OF THE PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE

      Medical journal of Australia
    22. BIRKETT DJ
      PHARMACEUTICAL BENEFITS ADVISORY-COMMITTEE - SOME QUESTIONS - REPLY

      Medical journal of Australia
    23. TASSANEEYAKUL W; BIRKETT DJ; EDWARDS JW; VERONESE ME; TASSANEEYAKUL W; TUKEY RH; MINERS JO
      HUMAN CYTOCHROME-P450 ISOFORM SPECIFICITY IN THE REGIOSELECTIVE METABOLISM OF TOLUENE AND O-XYLENE, M-XYLENE AND P-XYLENE

      The Journal of pharmacology and experimental therapeutics
    24. MINERS JO; COULTER S; TUKEY RH; VERONESE ME; BIRKETT DJ
      CYTOCHROME P450, 1A2, AND 2C9 ARE RESPONSIBLE FOR THE HUMAN HEPATIC O-DEMETHYLATION OF R-NAPROXEN AND S-NAPROXEN

      Biochemical pharmacology
    25. BIRKETT DJ; MCMANUS P
      MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDYIN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THETRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE

      British journal of clinical pharmacology
    26. MINERS JO; REES DLP; VALENTE L; VERONESE ME; BIRKETT DJ
      HUMAN HEPATIC CYTOCHROME-P450 2C9 CATALYZES THE RATE-LIMITING PATHWAYOF TORSEMIDE METABOLISM

      The Journal of pharmacology and experimental therapeutics
    27. TASSANEEYAKUL W; BIRKETT DJ; VERONESE ME; MCMANUS ME; TUKEY RH; MINERS JO
      DIRECT CHARACTERIZATION OF THE SELECTIVITY OF FURAFYLLINE AS AN INHIBITOR OF HUMAN CYTOCHROMES P450 1A1 AND 1A2

      Pharmacogenetics
    28. ANDERSSON T; MINERS JO; VERONESE ME; BIRKETT DJ
      DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS

      British journal of clinical pharmacology
    29. ANDERSSON T; MINERS JO; VERONESE ME; BIRKETT DJ
      IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM

      British journal of clinical pharmacology
    30. BIRKETT DJ; REES D; ANDERSSON T; GONZALEZ FJ; MINERS JO; VERONESE ME
      IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE

      British journal of clinical pharmacology
    31. DAY RO; BIRKETT DJ; HICKS N; MINERS JO; GRAHAM GG; BROOKS PM
      NEW USES FOR ALLOPURINOL

      Drugs
    32. ANDERSSON T; MINERS JO; BIRKETT DJ
      DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS

      Clinical pharmacology and therapeutics
    33. TASSANEEYAKUL W; BIRKETT DJ; MCMANUS ME; TASSANEEYAKUL W; VERONESE ME; ANDERSSON T; TUKEY RH; MINERS JO
      CAFFEINE METABOLISM BY HUMAN HEPATIC CYTOCHROMES P450 - CONTRIBUTIONSOF 1A2, 2E1 AND 3A ISOFORMS

      Biochemical pharmacology
    34. MANT A; WHICKER SD; MCMANUS P; BIRKETT DJ; EDMONDS D; DUMBRELL D
      BENZODIAZEPINE UTILIZATION IN AUSTRALIA - REPORT FROM A NEW PHARMACOEPIDEMIOLOGIC DATABASE

      Australian journal of public health
    35. VERONESE ME; MINERS JO; REES DLP; BIRKETT DJ
      TOLBUTAMIDE HYDROXYLATION IN HUMANS - LACK OF BIMODALITY IN 106 HEALTHY-SUBJECTS

      Pharmacogenetics
    36. ANDERSSON T; LAGERSTROM PO; MINERS JO; VERONESE ME; WEIDOLF L; BIRKETT DJ
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR HUMAN LIVER MICROSOMAL OMEPRAZOLE METABOLISM

      Journal of chromatography. Biomedical applications
    37. ANDERSSON T; MINERS JO; VERONESE ME; TASSANEEYAKUL W; TASSANEEYAKUL W; MEYER UA; BIRKETT DJ
      IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM

      British journal of clinical pharmacology
    38. TASSANEEYAKUL W; BIRKETT DJ; VERONESE ME; MCMANUS ME; TUKEY RH; QUATTROCHI LC; GELBOIN HV; MINERS JO
      SPECIFICITY OF SUBSTRATE AND INHIBITOR PROBES FOR HUMAN CYTOCHROMES-P450 1A1 AND 1A2

      The Journal of pharmacology and experimental therapeutics
    39. TASSANEEYAKUL W; VERONESE ME; BIRKETT DJ; GONZALEZ FJ; MINERS JO
      VALIDATION OF 4-NITROPHENOL AS AN IN-VITRO SUBSTRATE PROBE FOR HUMAN LIVER CYP2E1 USING CDNA EXPRESSION AND MICROSOMAL KINETIC TECHNIQUES

      Biochemical pharmacology
    40. BIRKETT DJ; MACKENZIE PI; VERONESE ME; MINERS JO
      IN-VITRO APPROACHES CAN PREDICT HUMAN DRUG-METABOLISM

      Trends in pharmacological sciences


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/02/20 alle ore 05:30:29